Carterra is pleased to invite you to their upcoming symposia focused on high-throughput drug discovery and antibody therapeutics. Industry and academic scientists will present new paradigms in discovery, applications and workflows including HT-SPR.
View titles/abstracts and register at one of the following location:
This will be a great time to network with industry leaders and discover new ways to enhance your research. Snacks and lunch will be provided. We look forward to seeing you!
Do you have questions? Please reach out to Cheri Salazar, Sr. Marketing Manager, at firstname.lastname@example.org.
Keynotes and presentations from scientists at:
You can view the slides from some of the presentations below.
Bill Harriman, PhD, SVP, Antibody Discovery, OmniAb
Use of high throughput antibody characterization to validate novel transgenic animal platforms
Abstract: Engineered animals designed to produce human sequence antibodies can be evaluated and compared via antibody repertoire analysis at the nucleic acid level, however this approach does not capture antibody specificity profiles and “functional diversity” that may be present at the paratope level. We have generated over 20 different genetic configurations during the past decade, and have routinely evaluated the corresponding immune repertoires through the functional analysis of panels of antigen-specific mAbs using high throughput epitope binning and kinetics analysis. This type of characterization is also critical downstream, in workflows focused on hit expansion and antibody optimization that leverage deep phenotypic screening, NGS datasets, and structural modeling methods.
Kendra Avery, PhD, Associate Director, Xencor
Discovery and characterization of Fvs for Anti-CD28 bi- and tri-specific antibodies to treat solid tumors
Abstract: T cells in the tumor microenvironment (TME) require both signal one and signal two for complete activation. Providing tumor targeted, anti-CD28, signal 2 may enhance the complete activation of T cells in the TME to provide a robust anti-tumor effect. In this presentation, I will describe some of the discovery and characterization efforts of the tumor associated antigen (TAA) arms of XmAb808, an Anti-B7-H3 x Anti-CD28 2+1 antibody, currently in phase 1 clinical trials for a wide variety of solid tumor types, and Anti-PD-L1 x Anti-PD-L2 x Anti-CD28, a tri-specific antibody in pre-clinical development.
Matthew Greving, PhD, VP, Machine Learning and Platform Technologies, iBio
High-throughput SPR to screen and train machine learning designed antibody libraries
Abstract: Antibody discovery efficiency and quality can be enhanced with machine learning. A lack of high-quality activity data at a scale sufficient to test and train models is a major limitation in the integration of machine learning and antibody discovery. We will present the use of high throughput Carterra LSA binding screens to test activity and accuracy of machine learning designed antibody libraries. In addition, we will present the use of high throughput Carterra LSA binding screens to train a machine learning model that predicts high-affinity antibodies for a target.
Zara Frizell, PhD, Associate Scientist, Sanofi
How Carterra LSA enables high-throughput binding assessment of NANOBODY® molecules
Abstract: The variable domain of heavy chain-only antibodies from camelids, referred to as NANOBODY molecule, offers numerous advantages for the development of biological drugs. Sanofi Ghent has pioneered the development of this new modality. Following the classical drug development process, one of the most important parameters we are looking at in early screenings is the binding strength of the NANOBODY molecule to its target. This talk will highlight practical aspects and considerations to set up NANOBODY-specific binding assays on the Carterra LSA that have become broadly applicable during lead identification and characterization steps in the Discovery department of Sanofi Ghent.